Physician profile
Robert G Courgi
NPI 1447336052
$7,033.01
in general payments reported to CMS, 2019-2025
34 companies · $972 in 2025
The $972 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $385 · 2021: $1,298 · 2022: $1,589 · 2023: $1,379 · 2024: $1,074 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,126.83 | 2019-2024 | Xarelto |
| Shionogi INC | $646.84 | 2021-2024 | Fetroja |
| Pfizer INC. | $625.64 | 2019-2025 | |
| Abbvie INC. | $610.82 | 2021-2025 | Teflaro, Avycaz |
| Astrazeneca Pharmaceuticals LP | $525.85 | 2019-2024 | Andexxa |
| Melinta Therapeutics, LLC | $520.89 | 2021-2025 | Kimyrsa, Orbactiv, Vabomere |
| Merck Sharp & Dohme LLC | $430.70 | 2019-2024 | Zerbaxa, Recarbrio, Dificid |
| Lilly USA, LLC | $336.46 | 2023-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $290.57 | 2019-2023 | Eliquis |
| Mylan Specialty L.P. | $241.80 | 2020-2022 | |
| Gilead Sciences, INC. | $177.13 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $169.10 | 2025 | |
| Sanofi-Aventis U.S. LLC | $162.10 | 2024-2025 | |
| Medtronic, INC. | $159.27 | 2024 | Cd Horizon Spinal System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.41 | 2022-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $136.63 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $100.68 | 2024-2025 | Omnipod |
| Cumberland Pharmaceuticals, INC. | $77.99 | 2022-2023 | Caldolor |
| La Jolla Pharmaceutical Company | $76.06 | 2023 | Xerava |
| Fisher Scientific Company L.L.C. | $63.29 | 2023-2024 | Procalcitonin |
| Regeneron Healthcare Solutions, INC. | $45.37 | 2022-2023 | Dupixent |
| Paratek Pharmaceuticals, INC. | $40.13 | 2021 | |
| Corcept Therapeutics | $35.78 | 2025 | Korlym |
| Janssen Scientific Affairs, LLC | $35.70 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $34.55 | 2020 | |
| Allergan, INC. | $33.48 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $24.85 | 2024 | Jynarque |
| Bioxcel Therapeutics, INC. | $24.25 | 2023 | Igalmi |
| Ascendis Pharma Endocrinology INC | $24.00 | 2025 | Yorvipath |
| Reprise Biomedical, INC. | $23.46 | 2023 | Miro3d |
| Bayer Healthcare Pharmaceuticals INC. | $23.05 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.54 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $20.61 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $18.18 | 2025 | Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Courgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.